<!DOCTYPE HTML>
<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"><meta name="viewport" content="width=device-width, initial-scale=1.0"><title>Pharmacological Management</title><script>
    // Set up general environment info
    window.Xyleme                                   = window.Xyleme || {};
    window.Xyleme.environment                       = window.Xyleme.environment || {};

    window.Xyleme.environment.type                  = 'web';
    window.Xyleme.environment.outputType            = 'OnlineCourse[REL_Modern]';
    window.Xyleme.environment.LMS                   = '';
    window.Xyleme.environment.SCORM_TYPE            = 'Static SCORM 1.2';
    window.Xyleme.environment.IS_AICC               = false;
    window.Xyleme.environment.lang                  = 'en';
    // The cache-bust value based on Promotion Time of the output as opposed to runtime
    window.Xyleme.environment.BUILD_TIME_CACHE_BUST = 'buildTime=14%3A53%3A49.548Z';
    // Whether or not to allow the caching of content during previews (or CDS/BCP previews)
    window.Xyleme.environment.ALLOW_PREVIEW_CACHING = false;
    window.Xyleme.environment.IS_DEPLOY             = true;

    // Determine if we are in a Review Session based on the value (or existence) of the "el" param
    window.Xyleme.environment.ReviewSession = false;

    // The request ID of the preview, used to create a preview scope with the server:
    window.Xyleme.environment.REQUEST_ID            = '';

    // The Regular Expression to identify a guid
    window.Xyleme.environment.GUID_REGEX            = /(\w{8}-(\w{4}-){3}\w{12}|\w{8}-\w{8}-\w{5}-\w{4}-\w{16})(_xref)?/;

    window.Xyleme.environment.FRAGMENT_CACHING_AVAILABLE = false;

    window.Xyleme.environment.CLOUDFRONT_BASE_URL = '';

    window.Xyleme.environment.XPE_PUBLIC_VERSION = '2025.04.10';
    window.Xyleme.environment.XPE_PUBLIC_VERSION_INT = 2025050;
    window.Xyleme.environment.XPE_BUILD_VERSION = '2025.04.10';
    window.Xyleme.environment.XPE_BUILD_VERSION_INT = 2025050;

    // Will be depreciated in the future
    window.LMS                                      = window.Xyleme.environment.LMS;
    window.SCORM_TYPE                               = window.Xyleme.environment.SCORM_TYPE;
    window.IS_AICC                                  = window.Xyleme.environment.IS_AICC;

    /*
     * WPS-2952
     * Ensure that if the "window.onload" event fires before the entirety of the
     * application JavaScript has loaded (as it will be loaded in asynchronously)
     * that we inform it that page content has already been loaded, including images
     * (this is required for page-specific preview and CDS Learning Object previews)
     */
    window.Xyleme.environment.loaded = false;
    window.addEventListener('load', function xySetWindowLoaded () {
        window.removeEventListener('load', xySetWindowLoaded, false);
        window.Xyleme.environment.loaded = true;
    });
</script><link href="css/application.css?cacheBust=14%3A53%3A49.548Z" rel="stylesheet" type="text/css" media="all"><script>
        var require = {
            map: {
                '*': {
                    'app/courseApi': 'js/app/courseApi.test.mock.js',
                    'app/player/integration': 'js/app/player/integration.test.mock.js'
                }
            }
        };
    </script><script src="js/vendor/require/detectUserAgent.js?cacheBust=14%3A53%3A49.548Z"></script><script src="js/vendor/require/browserCheck.js?cacheBust=14%3A53%3A49.548Z"></script><script>
    window.XYLEME_MODULES_CONFIG     = {
    "skin/components/calculator/calculator": {"width": "280px"},
    "checkBrowser": {
        "unsupportedBrowser": [
            {
                "browser": "IE",
                "description": "Internet Explorer 10",
                "version": "10"
            },
            {
                "browser": "IE",
                "description": "Internet Explorer 11",
                "version": "11"
            },
            {
                "browser": "Edge",
                "description": "Legacy MS Edge"
            }
        ],
        "enabled": true
    },
    "elements/procedure/procedure": {"expandFirstStep": false},
    "threeSixty": {"initialReverse": false},
    "skin/components/navigationTree/navigationTree": {
        "manualExpansion": false,
        "collapseContainer": false
    },
    "skin/components/courseProgress/courseProgress": {"compactMode": true},
    "global": {
        "contentScrollingContainerSelector": "#PageBody",
        "contentContainerSelector": "#PageBody",
        "useLegacyPlayer": false
    },
    "skin/regions/content/content": {
        "enableSwipeContentDrag": "true",
        "enableSwipeNavigation": "true"
    },
    "skin/regions/menu/menu": {
        "componentLinkDisplay": {
            "icon": true,
            "safe": true,
            "text": false
        },
        "resizeComponentLinks": false
    },
    "elements/categories/categories": {"startOpen": false},
    "elements/carouselTabs/carouselTabs": {"adaptiveHeight": false},
    "skin/components/notebook/notebook": {"linkAction": "show"},
    "app/questionApi": {"incompleteQuestionNavigation": {
        "next": false,
        "previous": true
    }},
    "elements/questions/question/view": {"supplementOverlayBehavior": "static"},
    "skin/components/visualQueue/visualQueue": {"pageWrapSelector": "#PageBody"},
    "skin/components/visualCue/visualCue": {
        "pageWrapSelector": "#PageBody",
        "renderForPC": true,
        "renderForDevices": true
    }
};

    /*
     * Attempt to capture uncaught errors and inform the user that the course may not run
     * as expected.
     *
     * @TODO This is incomplete, as it currently only prints to the console. The original
     *       functionality of showing a popup to the user was scrapped because there were
     *       too many errors being shown. Will need to be reworked.
     */
    if (window.XYLEME_MODULES_CONFIG && !window.XYLEME_MODULES_CONFIG.global.debugMode) {
        window.addEventListener('error', function(e) {
            if (window.console) {
                if (window.console.error) {
                    window.console.error('A fatal error occurred. Please refresh the page to try again. If this issue continues, please contact an administrator');
                } else if (window.console.log) {
                    window.console.log('A fatal error occurred. Please refresh the page to try again. If this issue continues, please contact an administrator');
                }
            }
            return true;
        });
    }

    /*
     * PI-1207
     * https://issues.xyleme.com/browse/PI-1207
     * Detect the user agent string and  jsConfig for this module.
     * Check all browsers from config and show modal window with error if f.e. explorer is being used.
     */

    var userAgentParse = detect.parse(navigator.userAgent);
    browserCheck(userAgentParse, 'This web browser will not provide the best experience for this content. Please use a supported browser to continue.',  window.XYLEME_MODULES_CONFIG['checkBrowser'])

</script><script>
window.XYLEME_OUTPUT_PROFILE_WAB = {
    
        showmarginnotes: 'true',
    
};
</script><script src="js/vendor/require/require.js?cacheBust=14%3A53%3A49.548Z"></script><script src="js/vendor/require/config.js?cacheBust=14%3A53%3A49.548Z"></script><script src="js/vendor/require/runtimeConfig.js?cacheBust=14%3A53%3A49.548Z"></script></head><body lang="en"><svg width="0" height="0" id="SVGIconsContainer"><defs><g id="text-bubble"><path d="M20 2h-16c-1.1 0-1.99.9-1.99 2l-.01 18 4-4h14c1.1 0 2-.9 2-2v-12c0-1.1-.9-2-2-2zm-11 9h-2v-2h2v2zm4 0h-2v-2h2v2zm4 0h-2v-2h2v2z"></path><path d="M0 0h24v24h-24z" fill="none"></path></g><g id="menu"><path d="M3,18h18v-2H3V18z M3,13h18v-2H3V13z M3,6v2h18V6H3z"></path></g><g id="arrow-left"><polygon points="15.4,7.4 14,6 8,12 14,18 15.4,16.6 10.8,12 "></polygon></g><g id="arrow-right"><polygon points="10,6 8.6,7.4 13.2,12 8.6,16.6 10,18 16,12 "></polygon></g><g id="exit"><path d="M10.1,15.6l1.4,1.4l5-5l-5-5l-1.4,1.4l2.6,2.6H3v2h9.7L10.1,15.6z M19,3H5C3.9,3,3,3.9,3,5v4h2V5h14v14H5v-4H3v4c0,1.1,0.9,2,2,2h14c1.1,0,2-0.9,2-2V5C21,3.9,20.1,3,19,3z"></path></g><g id="toc"><path d="M4,14h4v-4H4V14z M4,19h4v-4H4V19z M4,9h4V5H4V9z M9,14h12v-4H9V14z M9,19h12v-4H9V19z M9,5v4h12V5H9z"></path></g><g id="notebook"><path d="M19,2h-4.2c-0.4-1.2-1.5-2-2.8-2c-1.3,0-2.4,0.8-2.8,2H5C3.9,2,3,2.9,3,4v16c0,1.1,0.9,2,2,2h14c1.1,0,2-0.9,2-2V4C21,2.9,20.1,2,19,2z M12,2c0.6,0,1,0.4,1,1s-0.4,1-1,1c-0.6,0-1-0.4-1-1S11.4,2,12,2z M19,20H5V4h2v3h10V4h2V20z"></path></g><g id="glossary"><path d="M17,3H7C5.9,3,5,3.9,5,5l0,16l7-3l7,3V5C19,3.9,18.1,3,17,3z"></path></g><g id="bibliography"><path d="M21,5C19.89,4.65 18.67,4.5 17.5,4.5C15.55,4.5 13.45,4.9 12,6C10.55,4.9 8.45,4.5 6.5,4.5C4.55,4.5 2.45,4.9 1,6V20.65C1,20.9 1.25,21.15 1.5,21.15C1.6,21.15 1.65,21.1 1.75,21.1C3.1,20.45 5.05,20 6.5,20C8.45,20 10.55,20.4 12,21.5C13.35,20.65 15.8,20 17.5,20C19.15,20 20.85,20.3 22.25,21.05C22.35,21.1 22.4,21.1 22.5,21.1C22.75,21.1 23,20.85 23,20.6V6C22.4,5.55 21.75,5.25 21,5M21,18.5C19.9,18.15 18.7,18 17.5,18C15.8,18 13.35,18.65 12,19.5V8C13.35,7.15 15.8,6.5 17.5,6.5C18.7,6.5 19.9,6.65 21,7V18.5Z"></path></g><g id="sectionStatus"><path d="M7.9,10.1l-1.4,1.4L11,16L21,6l-1.4-1.4L11,13.2L7.9,10.1z M19,19L5,19V5h10V3H5C3.9,3,3,3.9,3,5v14c0,1.1,0.9,2,2,2h14c1.1,0,2-0.9,2-2v-8h-2V19z"></path></g><g id="mute"><path d="M16.5,12c0-1.8-1-3.3-2.5-4v2.2l2.5,2.5C16.5,12.4,16.5,12.2,16.5,12z M19,12c0,0.9-0.2,1.8-0.5,2.6l1.5,1.5c0.7-1.2,1-2.7,1-4.2c0-4.3-3-7.9-7-8.8v2.1C16.9,6.2,19,8.8,19,12z M4.3,3L3,4.3L7.7,9H3c0,0,0,6,0,6h4l5,5v-6.7l4.3,4.3c-0.7,0.5-1.4,0.9-2.3,1.2v2.1c1.4-0.3,2.6-0.9,3.7-1.8l2,2l1.3-1.3l-9-9L4.3,3z M12,4L9.9,6.1L12,8.2V4z"></path></g><g id="unmute"><path d="M3 9v6h4l5 5V4L7 9H3zm13.5 3c0-1.77-1.02-3.29-2.5-4.03v8.05c1.48-.73 2.5-2.25 2.5-4.02zM14 3.23v2.06c2.89.86 5 3.54 5 6.71s-2.11 5.85-5 6.71v2.06c4.01-.91 7-4.49 7-8.77s-2.99-7.86-7-8.77z"></path><path d="M0 0h24v24H0z" fill="none"></path></g><g id="muteunmute"><g id="mutetoggle"><path d="M16.5,12c0-1.8-1-3.3-2.5-4v2.2l2.5,2.5C16.5,12.4,16.5,12.2,16.5,12z M19,12c0,0.9-0.2,1.8-0.5,2.6l1.5,1.5c0.7-1.2,1-2.7,1-4.2c0-4.3-3-7.9-7-8.8v2.1C16.9,6.2,19,8.8,19,12z M4.3,3L3,4.3L7.7,9H3c0,0,0,6,0,6h4l5,5v-6.7l4.3,4.3c-0.7,0.5-1.4,0.9-2.3,1.2v2.1c1.4-0.3,2.6-0.9,3.7-1.8l2,2l1.3-1.3l-9-9L4.3,3z M12,4L9.9,6.1L12,8.2V4z"></path></g><g id="unmutetoggle"><path d="M3 9v6h4l5 5V4L7 9H3zm13.5 3c0-1.77-1.02-3.29-2.5-4.03v8.05c1.48-.73 2.5-2.25 2.5-4.02zM14 3.23v2.06c2.89.86 5 3.54 5 6.71s-2.11 5.85-5 6.71v2.06c4.01-.91 7-4.49 7-8.77s-2.99-7.86-7-8.77z"></path><path d="M0 0h24v24H0z" fill="none"></path></g></g><g id="print"><path d="M19,8H5c-1.7,0-3,1.3-3,3v6h4v4h12v-4h4v-6C22,9.3,20.7,8,19,8z M16,19H8v-5h8V19z M19,12c-0.6,0-1-0.4-1-1s0.4-1,1-1c0.6,0,1,0.4,1,1S19.6,12,19,12z M18,3H6v4h12V3z"></path></g><g id="calculator"><path d=" M6,1C4.9,1,4,1.9,4,3c0,1.1,0.9,2,2,2s2-0.9,2-2C8,1.9,7.1,1,6,1z M6,7C4.9,7,4,7.9,4,9c0,1.1,0.9,2,2,2s2-0.9,2-2C8,7.9,7.1,7,6,7z M6,13c-1.1,0-2,0.9-2,2c0,1.1,0.9,2,2,2s2-0.9,2-2C8,13.9,7.1,13,6,13z M18,5c1.1,0,2-0.9,2-2c0-1.1-0.9-2-2-2s-2,0.9-2,2C16,4.1,16.9,5,18,5z M12,13c-1.1,0-2,0.9-2,2c0,1.1,0.9,2,2,2s2-0.9,2-2C14,13.9,13.1,13,12,13z M18,13c-1.1,0-2,0.9-2,2c0,1.1,0.9,2,2,2s2-0.9,2-2C20,13.9,19.1,13,18,13z M18,7c-1.1,0-2,0.9-2,2c0,1.1,0.9,2,2,2s2-0.9,2-2C20,7.9,19.1,7,18,7z M12,7c-1.1,0-2,0.9-2,2c0,1.1,0.9,2,2,2s2-0.9,2-2C14,7.9,13.1,7,12,7z M12,1c-1.1,0-2,0.9-2,2c0,1.1,0.9,2,2,2s2-0.9,2-2C14,1.9,13.1,1,12,1z"></path></g><g id="resources"><path d="M6,2C4.9,2,4,2.9,4,4l0,16c0,1.1,0.9,2,2,2h12c1.1,0,2-0.9,2-2V8l-6-6H6z M13,9V3.5L18.5,9H13z"></path></g><g id="narration"><path d="M18,17H6v-2h12V17z M18,13H6v-2h12V13z M18,9H6V7h12V9z M3,22l1.5-1.5L6,22l1.5-1.5L9,22l1.5-1.5L12,22l1.5-1.5L15,22l1.5-1.5L18,22l1.5-1.5L21,22V2l-1.5,1.5L18,2l-1.5,1.5L15,2l-1.5,1.5L12,2l-1.5,1.5L9,2L7.5,3.5L6,2L4.5,3.5L3,2V22z"></path></g><g id="submit-all"><path d="M18,7l-1.4-1.4l-6.3,6.3l1.4,1.4L18,7z M22.2,5.6L11.7,16.2L7.5,12l-1.4,1.4l5.6,5.6l12-12L22.2,5.6z M0.4,13.4L6,19l1.4-1.4L1.8,12L0.4,13.4z"></path></g><g id="retake"><path d="M12,5V1.5l-5,5l5,5V7c3.3,0,6,2.7,6,6s-2.7,6-6,6c-3.3,0-6-2.7-6-6H4c0,4.4,3.6,8,8,8c4.4,0,8-3.6,8-8S16.4,5,12,5z"></path></g><g id="submit"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g><g id="visual-cue"><path d="M19.05 8.94L11.03 3L3 8.94L8.22 8.94L8.22 17.06L3 17.06L11.02 23L19.05 17.06L13.83 17.06L13.83 8.94L19.05 8.94Z"></path></g><g id="unflag"><path d="M1 23 V1 H20 L15 8 L20 16 L1 16" stroke-width="2" fill="none"></path></g><g id="flag"><path d="M1 23 V1 H20 L15 8 L20 16 L1 16" stroke-width="2" fill="inherit"></path></g><g id="drag-handle"><path d="M20 9H4v2h16V9zM4 15h16v-2H4v2z"></path></g><g id="swap-vertical"><path d="M16 17.01V10h-2v7.01h-3L15 21l4-3.99h-3zM9 3L5 6.99h3V14h2V6.99h3L9 3z"></path></g><g id="close"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g><g id="correct"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g><g id="incorrect"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g><g id="alsocorrect"><path d="M0 0h24v24H0z" fill="none"></path><path d="M12 2C6.47 2 2 6.47 2 12s4.47 10 10 10 10-4.47 10-10S17.53 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8z"></path></g><g id="imagemap"><g class="MarkCheck"><path stroke-width="2" d="m8.33117,14.57541c0.09216,0.11874 0.21456,0.17858 0.33622,0.17858c0.12092,0 0.24258,-0.05889 0.33622,-0.17858l6.06006,-7.80926c0.18581,-0.23938 0.18581,-0.62599 0,-0.86537c-0.18581,-0.23938 -0.4859,-0.23938 -0.6717,0l-5.72458,7.3742l-2.89989,-3.73317c-0.18581,-0.23843 -0.48663,-0.23843 -0.6717,0c-0.18581,0.23938 -0.18581,0.62694 0,0.86537l3.23538,4.16823z"></path></g></g></defs></svg><div id="PageMain" class="Main" data-grid=""><div id="PageOuterWrap" class="OuterWrap" data-grid="row"><div id="PageInnerWrap" class="InnerWrap" data-grid="small-24 columns"><div class="Body" data-grid=""><div class="FragmentSkinComponentWrapper"><a class="ComponentLink GlossaryLink " data-component="glossary" tabindex="0" title="Glossary"><svg viewBox="0 0 24 24" class="SVGIcon ComponentLinkIcon GlossaryIcon" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="glossary"><path d="M17,3H7C5.9,3,5,3.9,5,5l0,16l7-3l7,3V5C19,3.9,18.1,3,17,3z"></path></g></svg><span class="ComponentLinkTitle GlossaryTitle ">Glossary</span></a><a class="ComponentLink CourseResourcesLink " data-component="courseResources" tabindex="0" title="Resources"><svg viewBox="0 0 24 24" class="SVGIcon ComponentLinkIcon CourseResourcesIcon" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="resources"><path d="M6,2C4.9,2,4,2.9,4,4l0,16c0,1.1,0.9,2,2,2h12c1.1,0,2-0.9,2-2V8l-6-6H6z M13,9V3.5L18.5,9H13z"></path></g></svg><span class="ComponentLinkTitle CourseResourcesTitle ">Resources</span></a><a class="ComponentLink PageResourcesLink " data-component="pageResources" tabindex="0" title="Page Resources"><svg viewBox="0 0 24 24" class="SVGIcon ComponentLinkIcon PageResourcesIcon" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="resources"><path d="M6,2C4.9,2,4,2.9,4,4l0,16c0,1.1,0.9,2,2,2h12c1.1,0,2-0.9,2-2V8l-6-6H6z M13,9V3.5L18.5,9H13z"></path></g></svg><span class="ComponentLinkTitle PageResourcesTitle ">Page Resources</span></a><div class="ComponentContent CourseResourcesContent" data-component="courseResources"><div class="ResourcesContainer"><div class="Resources CourseResourcesContainer"><div class="Heading">Course Resources</div><div class="Index"></div><div class="Contents"><div class="Supplements"><div class="Supplement" tabindex="0" aria-expanded="false" aria-keyshortcuts="Enter Space" aria-controls="CourseResources-Help-type"><a href="#">Help</a></div><div class="Resources Closed" id="CourseResources-Help-type"><div class="Resource" data-resource-type="ExternalLink"><a href="#" tabindex="0" aria-expanded="false" aria-keyshortcuts="Enter" class="Title ResourcesItem CourseResourceItem" aria-controls="CourseResources-b689d2a1-b727-4d1a-8904-fc92baa80be3-content">Course Help</a><div class="SupplementItem Closed" data-guid="b689d2a1-b727-4d1a-8904-fc92baa80be3" id="CourseResources-b689d2a1-b727-4d1a-8904-fc92baa80be3-content"><a class="ExternalLink" href="https://preview.relias.com/library/demo/help_xy18/index.html" target="_blank">Course Help</a></div></div><div class="Resource" data-resource-type="ExternalLink"><a href="#" tabindex="0" aria-expanded="false" aria-keyshortcuts="Enter" class="Title ResourcesItem CourseResourceItem" aria-controls="CourseResources-fd9722be-8abd-4dce-bf2a-306430feef81-content">Special Accommodations</a><div class="SupplementItem Closed" data-guid="fd9722be-8abd-4dce-bf2a-306430feef81" id="CourseResources-fd9722be-8abd-4dce-bf2a-306430feef81-content"><a class="ExternalLink" href="https://www.relias.com/support" target="_blank">Special Accommodations</a></div></div></div></div></div></div></div></div><div class="ComponentContent GlossaryContent" data-component="glossary"><div id="MainMenuGlossaryContainer" class="GlossaryContainer"><div class="Glossary"><div class="Index"></div><div class="Contents"></div></div></div></div><div class="ComponentContent PageResourcesContent" data-component="pageResources"></div></div><div id="PageBody" class="Body LoadingFragment"><div class="Topic"><h1 class="Title" id="92a10e43-0706-4f2e-8b84-6f29bd790c4c---cid-d2e786-">Pharmacological Management</h1><div class="PageDocumentTitle">Pharmacology of Antiemetics — Copy</div><div class="ParaBlock" id="b4396e6e-a8b6-40e3-bbc9-219d57104465"><div class="List" id="f4522455-0a5f-4ab5-8810-f30fa4f8aece" data-build=""><div class="ListPreamble">For nausea and vomiting that is not manageable with nonpharmacological interventions, antiemetic drugs are available and can be divided into the following classes:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Dopamine receptor antagonists</div></li><li class="ListItem"><div class="RichText">Serotonin receptor antagonists</div></li><li class="ListItem"><div class="RichText">Anticholinergic agents</div></li><li class="ListItem"><div class="RichText">Antihistamines</div></li><li class="ListItem"><div class="RichText">Neurokinin receptor antagonists</div></li><li class="ListItem"><div class="RichText">Glucocorticoids</div></li><li class="ListItem"><div class="RichText">Benzodiazepines</div></li><li class="ListItem"><div class="RichText">Atypical antipsychotics</div></li><li class="ListItem"><div class="RichText">Cannabinoids</div></li></ul></div><div class="CustomNote vignette" data-popup="" style="width: auto; height: auto;"><div class="Icon"><img alt="" title="" src="media/XY_Media/New Notes/book_1313502372_g.png" style="width: 60px; height: 60px;"></div><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Take Note:</strong> Administering antiemetics to children when the cause is unknown is not recommended (Southard &amp; Khalili, 2022).</div></div></div></div></div><section class="TitledBlock" aria-labelledby="c80a6927-6838-4cea-9a57-4c42eed76b9c-title"><h1 id="c80a6927-6838-4cea-9a57-4c42eed76b9c-title">Dopamine Receptor Antagonists</h1><div class="ParaBlock" id="55c7dd1c-4c80-47dd-b3c7-837400f25b8c"><div class="List" id="2585a01c-f86b-459a-b4ab-ca9f2539343d" data-build=""><div class="ListPreamble">Dopamine receptor antagonists inhibit the dopamine receptors in the CTZ, leading to a reduction in nausea and vomiting (Welliver, 2014). Despite being inexpensive and effective, these medications have a broad range of side effects, including:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Sedation</div></li><li class="ListItem"><div class="RichText">Neuroleptic malignant syndrome</div></li><li class="ListItem"><div class="RichText">Agranulocytosis</div></li><li class="ListItem"><div class="RichText">Orthostatic hypotension</div></li><li class="ListItem"><div class="RichText">Extrapyramidal symptoms</div></li><li class="ListItem"><div class="RichText">Altered mental status (i.e., at higher doses)</div></li><li class="ListItem"><div class="RichText">QT prolongation</div></li></ul></div><div class="List" id="575a238d-62c4-46ed-a9a9-d2e76aa03075" data-build=""><div class="ListPreamble">Although rare, <strong>neuroleptic malignant syndrome </strong>(NMS) is a <strong>life-threatening </strong>adverse effect of dopamine receptor antagonists and exhibits the following signs and symptoms:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">High fever</div></li><li class="ListItem"><div class="RichText">Sweating</div></li><li class="ListItem"><div class="RichText">Tachycardia</div></li><li class="ListItem"><div class="RichText">“Lead pipe” muscular rigidity</div></li><li class="ListItem"><div class="RichText">Unstable blood pressure</div></li><li class="ListItem"><div class="RichText">Elevated white blood cell count</div></li><li class="ListItem"><div class="RichText">Altered mental status (e.g., stupor)</div></li><li class="ListItem"><div class="RichText">Cardiac arrhythmias</div></li><li class="ListItem"><div class="RichText">Irregular heart rate</div></li></ul></div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Safety Alert: </strong>When NMS is suspected, discontinue the medication and administer dantrolene (Dantrium<sup>®</sup>, Ryanodex<sup>®</sup>) immediately. This adverse effect is derived from the antidopaminergic action of these medications.</div></div></div></div><div class="RichText">QT prolongation, a rare adverse effect, occurs more often when given for CINV. Due to its adverse effect profile, dopamine antagonists have fallen out of use and have been replaced by serotonergic antagonists for the treatment of emesis (Welliver, 2014).</div><div class="List" id="265c9a91-55b2-441f-a571-7957b025a774" data-build=""><div class="ListPreamble">Classifications of dopamine antagonists include:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Phenothiazines (e.g., promethazine [Phenergan<sup>®</sup>], prochlorperazine [Compro<sup>®</sup>, Procomp<sup>®</sup>])</div></li><li class="ListItem"><div class="RichText">Substituted benzamides (e.g., metoclopramide [Reglan<sup>®</sup>, Metozolv<sup>®</sup>ODT])</div></li><li class="ListItem"><div class="RichText">Butyrophenones (e.g., droperidol [Inapsine<sup>®</sup>]) (not discussed in this course)</div></li></ul></div><div class="RichText"><strong>Promethazine</strong></div><div class="RichText"></div><div class="List" id="7a1bfbbf-68be-4641-b508-97d699a54d0d" data-build=""><div class="ListPreamble">A phenothiazine derivative, promethazine has unique qualities (Southard &amp; Khalili, 2022):</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Antidopaminergic</div></li><li class="ListItem"><div class="RichText">Anticholinergic</div></li><li class="ListItem"><div class="RichText">Antihistamine</div></li></ul></div><div class="List" id="d92591b9-36c0-4b7e-809f-961c93b06ec1" data-build=""><div class="ListPreamble">It is prescribed primarily for general nausea and vomiting and for more specific types of nausea and vomiting (Southard &amp; Khalili, 2022):</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">PONV</div></li><li class="ListItem"><div class="RichText">CINV</div></li><li class="ListItem"><div class="RichText">Pregnancy-related, including hyperemesis gravidarum (off-label indication)</div></li></ul></div><div class="RichText"><strong>Dosage and Administration</strong><br>Promethazine can be administered through several routes, such as orally, intramuscularly, intravenously, and rectally (Southard &amp; Khalili, 2022). Promethazine may be given without regard to meals. For general use in the control of nausea and vomiting, the recommended dose of promethazine is 12.5 to 25 mg in doses at least 4 hours apart.</div><div class="RichText">Promethazine may be administered at a dose of 25 to 75 mg IM or IV during the early stages of labor to provide sedation and relieve apprehension. For general pregnancy-related nausea and vomiting, it can be helpful in relieving symptoms when other antiemetics have been unsuccessful, but it should only be used if the benefit outweighs the potential risk to the fetus. </div><div class="Figure Wrap  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="adult taking motion sickness pill" title="adult taking motion sickness pill" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/pill-1407133468-g.jpg" style="width: 500px; max-height: 333px;" class="FigureImage"></div></div></div><div class="RichText">For motion sickness, the dose is 25 mg up to twice daily, with the initial dose taken 30 to 60 minutes before anticipated motion sickness. </div><div class="RichText">To prevent nausea and vomiting related to surgery, 50 mg can be administered by rectal suppository or oral tablet to adults the night before surgery with 25 to 50 mg used post-operatively.</div><div class="RichText"><strong>Adverse Effects and Contraindications<br></strong>Adverse effects are more common in older adults and range from confusion and drowsiness to tardive dyskinesia. Promethazine is no longer a first-line drug for nausea. Promethazine should not be used in children or adolescents who have vomiting of unknown etiology.</div><div class="RichText">Some adverse effects (some of which may be administration route dependent) for promethazine include:</div><div class="Tabs CarouselTabs Horizontal" role="tablist" id="a7a18962-12e1-4308-b891-36b27fbd0514" data-must-be-completed="true" data-orientation="Horizontal" style="width: auto; height: auto;"><div class="TabsInstructions"><sub><span class="Overline">Select the arrows to learn more.</span></sub></div><ul class="TabsNavigation Horizontal" role="tablist"><li class="TabsNavigationItem" data-tab="a7a18962-12e1-4308-b891-36b27fbd0514---cid-d2e995-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="a7a18962-12e1-4308-b891-36b27fbd0514-panel-1"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li><li class="TabsNavigationItem" data-tab="a7a18962-12e1-4308-b891-36b27fbd0514---cid-d2e1017-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="a7a18962-12e1-4308-b891-36b27fbd0514-panel-2"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li><li class="TabsNavigationItem" data-tab="a7a18962-12e1-4308-b891-36b27fbd0514---cid-d2e1039-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="a7a18962-12e1-4308-b891-36b27fbd0514-panel-3"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li><li class="TabsNavigationItem" data-tab="a7a18962-12e1-4308-b891-36b27fbd0514---cid-d2e1058-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="a7a18962-12e1-4308-b891-36b27fbd0514-panel-4"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li><li class="TabsNavigationItem" data-tab="a7a18962-12e1-4308-b891-36b27fbd0514---cid-d2e1077-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="a7a18962-12e1-4308-b891-36b27fbd0514-panel-5"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li></ul><div class="TabsPanels HiddenLoading Horizontal"><div class="TabsPanel" id="a7a18962-12e1-4308-b891-36b27fbd0514-panel-1" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="List" id="8ff44d56-5d6d-456d-8e38-6466d2829f3c" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">CNS effects</div><div class="List" id="8ff44d56-5d6d-456d-8e38-6466d2829f3c---cid-d2e999---cid-d2e1000---cid-d2e1003-" data-build=""><ul class="ListItems Disk " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Somnolence</div></li><li class="ListItem"><div class="RichText">Blurred vision</div></li><li class="ListItem"><div class="RichText">Dizziness</div></li><li class="ListItem"><div class="RichText">Confusion</div></li></ul></div></li></ul></div></div></div><div class="TabsPanel" id="a7a18962-12e1-4308-b891-36b27fbd0514-panel-2" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="List" id="3b824324-64e8-468f-8381-631ee7aef5b3" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Tissue effects (i.e., related to IV or IM routes)</div><div class="List" id="3b824324-64e8-468f-8381-631ee7aef5b3---cid-d2e1021---cid-d2e1022---cid-d2e1025-" data-build=""><ul class="ListItems Disk " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Phlebitis</div></li><li class="ListItem"><div class="RichText">Thrombophlebitis</div></li><li class="ListItem"><div class="RichText">Abscess</div></li><li class="ListItem"><div class="RichText">Tissue necrosis</div></li></ul></div></li></ul></div></div></div><div class="TabsPanel" id="a7a18962-12e1-4308-b891-36b27fbd0514-panel-3" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="List" id="61fa555d-d0ae-45a1-93f7-818651162c49" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Cardiovascular effects</div><div class="List" id="61fa555d-d0ae-45a1-93f7-818651162c49---cid-d2e1043---cid-d2e1044---cid-d2e1047-" data-build=""><ul class="ListItems Disk " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Blood pressure fluctuations (i.e., hypotension or hypertension)</div></li><li class="ListItem"><div class="RichText">Heart rate fluctuations (i.e., bradycardia or tachycardia)</div></li><li class="ListItem"><div class="RichText">Faintness</div></li></ul></div></li></ul></div></div></div><div class="TabsPanel" id="a7a18962-12e1-4308-b891-36b27fbd0514-panel-4" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="List" id="0446233f-8839-4981-a428-d55f91b00568" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Respiratory effects</div><div class="List" id="0446233f-8839-4981-a428-d55f91b00568---cid-d2e1062---cid-d2e1063---cid-d2e1066-" data-build=""><ul class="ListItems Disk " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Nasal stuffiness</div></li><li class="ListItem"><div class="RichText">Asthma</div></li><li class="ListItem"><div class="RichText">Apnea</div></li></ul></div></li></ul></div></div></div><div class="TabsPanel" id="a7a18962-12e1-4308-b891-36b27fbd0514-panel-5" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="List" id="f23f6abf-8d23-4eb9-b4c2-272aab2f834c" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Dermatologic</div><div class="List" id="f23f6abf-8d23-4eb9-b4c2-272aab2f834c---cid-d2e1081---cid-d2e1082---cid-d2e1085-" data-build=""><ul class="ListItems Disk " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Dermatitis</div></li><li class="ListItem"><div class="RichText">Photosensitivity</div></li></ul></div></li></ul></div></div></div></div></div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Safety Alert: </strong>The FDA has issued black-box warnings contraindicating use in pediatric patients younger than 2 years due to the possibility of fatal respiratory depression and warning of the risk of severe chemical irritation and tissue damage. Another black-box warning cautions that the injection form of promethazine can result in severe tissue damage, including gangrene.</div></div></div></div><div class="RichText"><strong>Prochlorperazine</strong></div><div class="RichText">Prochlorperazine is an antiemetic that has been FDA-approved to control severe nausea and vomiting.</div><div class="RichText"><strong>Dosage and Administration</strong><br>Prochlorperazine is available as an oral liquid, an injectable formulation, a tablet, and a suppository. Antiemetic effects are rapid and often last 4 to 6 hours.</div><div class="RichText">The dose of prochlorperazine varies with the indication and formulation. The lowest dose should always be used to initiate therapy and then adjusted on the basis of individual response. To control severe nausea and vomiting, particularly with PONV, the IM and oral dose is 5 to 10 mg repeated every 4 hours, with a maximum dose of 40 mg per day. The IV dose, administered by slow injection or infusion, is 2.5 to 10 mg, with a single dose not to exceed 10 mg and a total daily dose of no more than 40 mg. The initial rectal dose of prochlorperazine is 25 mg twice daily.</div><div class="Figure Wrapright  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="Fatty liver disease" title="Fatty liver disease" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/fattyliver-1258912790-g.jpg" style="width: 300px; max-height: 328px;" class="FigureImage"></div></div></div><div class="RichText"><strong>Adverse Effects<br></strong>In addition to extrapyramidal symptoms and cardiac conduction issues mentioned earlier, reports of adverse effects of prochlorperazine include (Din &amp; Preuss, 2023):<strong></strong></div><div class="List" id="4792e19a-c221-49d4-855e-e70f5e8204cb" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Decreased white blood cell count</div></li><li class="ListItem"><div class="RichText">Cholestatic jaundice</div></li><li class="ListItem"><div class="RichText">Fatty liver</div></li><li class="ListItem"><div class="RichText">Amenorrhea</div></li><li class="ListItem"><div class="RichText">Elevated levels of the prolactin hormone</div></li><li class="ListItem"><div class="RichText">Breast enlargement</div></li><li class="ListItem"><div class="RichText">Sexual dysfunction</div></li></ul></div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Safety Alert: </strong>Prochlorperazine’s adverse effects are enhanced in children and should be avoided (Din &amp; Preuss, 2023). Its label contains a black-box warning about the risk of increased mortality in older patients with dementia-related psychosis.</div></div></div></div><div class="RichText"><strong>Metoclopramide</strong></div><div class="RichText">Metoclopramide is FDA-approved to treat nausea and vomiting in patients with diabetic gastroparesis, gastroesophageal reflux disease (GERD), in those undergoing chemotherapy (i.e., specifically in the parenteral route), or PONV (Isola et al., 2023). Off-label indications for metoclopramide includes migraine treatment (i.e., especially in the emergency department setting).</div><div class="RichText">This drug is known to increase peristaltic movements of the proximal small bowel and relaxes the pyloric sphincter, which facilitates gastric emptying. Metoclopramide also acts as a dopamine antagonist, both peripherally and centrally, raising the nausea and vomiting threshold of the CTZ.</div><div class="RichText"><strong>Dosage and Administration</strong><br>Metoclopramide comes in forms of a tablet, oral solution, nasal spray, or sterile injections. The dose varies depending on the indication for use and the patient’s age. However, the usual oral dose of metoclopramide is 5 to 10 mg.</div><div class="RichText"><strong>Adverse Effects<br></strong>Advise against taking high doses of metoclopramide or sustaining long-term use of the drug (i.e., greater than 12 weeks). It may increase the patient’s risk of developing tardive dyskinesia, which is seen in over 10% of those who take metoclopramide for extended periods.</div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Practice Tip: </strong>When using dopaminergic antagonists, always warn patients about extrapyramidal symptoms. Once developed, dyskinesias are very difficult to treat.</div></div></div></div></div></section><section class="TitledBlock" aria-labelledby="fdee557c-c7d2-4001-9b1e-07b5ff3e3bad-title"><h1 id="fdee557c-c7d2-4001-9b1e-07b5ff3e3bad-title">Serotonin Receptor Antagonists</h1><div class="ParaBlock" id="d7308fdc-c090-4831-bdcd-870a7bdc5160"><div class="List" id="09976c21-4be0-4dd8-8c68-4adb4acb112e" data-build=""><div class="ListPreamble">Selective 5-HT3 blockers inhibit serotonin in two areas, the CTZ, causing a central antiemetic effect, and on the receptors of the vagus nerve, within the GI tract (peripheral antiemetic effect) (Theriot et al., 2022). These drugs have FDA approval for nausea and vomiting prophylaxis in the pediatric and adult population for after anesthesia and radiation therapy, and for CINV. This course will only highlight ondansetron (Zofran<sup>®</sup>, Zuplenz<sup>®</sup>) and granisetron (Sustol<sup>®</sup>, Sancuso<sup>®</sup>, Granisol<sup>®</sup>), but all of the current FDA-approved 5-HT3 blockers are listed below:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Ondansetron </div></li><li class="ListItem"><div class="RichText">Granisetron</div></li><li class="ListItem"><div class="RichText">Dolasetron (Anzemet<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Palonosetron (Aloxi<sup>®</sup>)</div></li></ul></div><div class="Figure Wrapright  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="Prolonged QT interval" title="Prolonged QT interval" aria-label="PeaBrainC, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0&gt;, via Wikimedia Commons" src="media/_RE-ORG/ACU/_NAR/POAEM/Long_QT_subtypes.jpg" style="width: 300px; max-height: 477px;" class="FigureImage"></div></div><div class="Caption" id="e5df5721-88f9-4349-913e-b9213cd8af18-caption"><sub><sup>PeaBrainC, CC BY-SA 4.0 &lt;https://creativecommons.org/licenses/by-sa/4.0&gt;, via Wikimedia Commons</sup></sub></div></div><div class="RichText">Overall, these drugs are safe and well-tolerated, with the most common side effects being headache, fatigue, and constipation (Theriot et al., 2022). If they are taken with other QT-interval-prolonging medications, QT prolongation can occur, though this risk appears to be higher with IV dosing of 5-HT3 inhibitors. In addition, 5-HT3 inhibitors can have rare, cardiac-related adverse effects, such as arrhythmias, ECG changes (e.g., ST segment depression), and cardiac arrest.</div><div class="RichText">When taken with other serotonergic agents (e.g., selective serotonin-reuptake inhibitors, monoamine oxidase inhibitors), the potential for serotonin syndrome exists (Gravatt et al., 2023).</div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Practice Tip: </strong>Patients should be aware of signs of serotonin syndrome that may occur with 5-HT3 receptor antagonists, such as mental status changes, labile blood pressure, dizziness, flushing, hyperthermia, tremor, rigidity, nausea, vomiting, diarrhea, and seizures (Gravatt et al., 2023).</div></div></div></div><div class="RichText">5-HT3 inhibitors are contraindicated for patients taking apomorphine (Apokyn<sup>®</sup>), which has resulted in loss of consciousness and significant low blood pressure with simultaneous use (Theriot et al., 2022).</div><div class="RichText"><strong>Ondansetron</strong></div><div class="RichText">Ondansetron is effective as an antiemetic for prophylaxis of CINV, radiation-induced nausea and vomiting, and PONV. It is also used off-label for the treatment of nausea and vomiting in pregnancy, although ACOG recommends that providers consider the use of ondansetron for pregnancy on a case-by-case basis (Smith et al., 2023). It is generally considered safe but fetal risk cannot be ruled out. Some studies have shown a very small occurrence of congenital anomalies with ondansetron use.</div><div class="RichText"><strong>Dosage and Administration<br></strong>For the prevention of CINV, ondansetron at 0.15 mg/kg IV (to a maximum single dose of 16 mg) is recommended 30 minutes before chemotherapy. The dose can be repeated 4 and 8 hours after the first dose. For the prevention of PONV, a single 4 mg IV dose prior to anesthesia is recommended.</div><div class="RichText">Oral ondansetron can be administered to prevent CINV and radiotherapy-induced nausea and vomiting. For CINV, an 8 mg dose is administered 30 minutes before the start of chemotherapy followed by a second dose 8 hours later. For a day or two after chemotherapy, 8 mg of ondansetron can be taken twice daily. For patients undergoing radiation therapy, 8 mg of ondansetron is administered 1 to 2 hours before the procedure. Depending on the type of therapy, ondansetron can be continued for a few days after radiation.</div><div class="RichText">To prevent PONV, 16 mg (two 8 mg ondansetron tablets) can be given an hour before induction of anesthesia. </div><div class="RichText"><strong>Adverse Effects<br></strong>Common adverse effects of ondansetron include (Griddine &amp; Bush, 2023):<strong></strong></div><div class="List" id="e902abb5-598e-413c-bdb8-eb666a5fe185" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Dry mouth</div></li><li class="ListItem"><div class="RichText">Headache</div></li><li class="ListItem"><div class="RichText">Dry mouth</div></li><li class="ListItem"><div class="RichText">Constipation</div></li><li class="ListItem"><div class="RichText">General discomfort</div></li></ul></div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Safety Alert: </strong>Use caution in patients with phenylketonuria (PKU), particularly in the tablet form, which may contain phenylalanine. This may result in permanent neurological injury.</div></div></div></div><div class="RichText"><strong>Granisetron</strong></div><div class="RichText">Granisetron is a 5-HT3 receptor antagonist approved for the prevention of CINV, radiation-induced nausea and vomiting, and PONV.</div><div class="RichText"><strong>Dosage and Administration<br></strong>Granisetron comes in the form of a tablet, oral solution, parenteral solution for injection, or a transdermal patch. Dosages include (Medscape, n.d.b.):</div><div class="Tabs CarouselTabs Horizontal" role="tablist" id="ff6f1c4f-1264-4c1f-a144-1bba8860146d" data-must-be-completed="true" data-orientation="Horizontal" style="width: auto; height: auto;"><div class="TabsInstructions"><sub><span class="Overline">Select the arrows to learn more.</span></sub></div><ul class="TabsNavigation Horizontal" role="tablist"><li class="TabsNavigationItem" data-tab="ff6f1c4f-1264-4c1f-a144-1bba8860146d---cid-d2e1291-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-1"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li><li class="TabsNavigationItem" data-tab="ff6f1c4f-1264-4c1f-a144-1bba8860146d---cid-d2e1302-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-2"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li><li class="TabsNavigationItem" data-tab="ff6f1c4f-1264-4c1f-a144-1bba8860146d---cid-d2e1313-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-3"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li><li class="TabsNavigationItem" data-tab="ff6f1c4f-1264-4c1f-a144-1bba8860146d---cid-d2e1329-" role="tab" tabindex="-1" aria-keyshortcuts="Enter" aria-selected="false" aria-controls="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-4"><span class="TabsPanelIndex"></span><a href="#" class="TabsPanelTitle"></a></li></ul><div class="TabsPanels HiddenLoading Horizontal"><div class="TabsPanel" id="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-1" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="RichText"></div><div class="List" id="9d9d3205-879c-4219-bb27-dade4bca980d" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText"><strong>IV administration</strong>: For adults and children 2 years and older, 10 mcg/kg IV is administered 30 minutes before chemotherapy.</div></li></ul></div></div></div><div class="TabsPanel" id="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-2" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="RichText"></div><div class="List" id="5d0a19f0-7bb8-4154-9f7e-c9b72e68b297" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText"><strong>Subcutaneous injection</strong>: For adults, 10 mg is given subcutaneously in the abdomen or the posterior side of the upper arm at least 30 minutes before the onset of chemotherapy (Day 1). A slow, uninterrupted injection should be given over 20 to 30 seconds to minimize the risk of injection site reactions. This can be repeated once every 7 days.</div></li></ul></div></div></div><div class="TabsPanel" id="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-3" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="RichText"></div><div class="List" id="e68f58fc-0fde-4d5f-9466-18e508ff5565" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText"><strong>Oral </strong><strong>tablet or solution: </strong>For adults, a 2 mg dose is given an hour before chemotherapy <strong>OR</strong> a 1 mg dose is given an hour before chemotherapy and a 1 mg dose is given 12 hours after the first dose.</div></li></ul></div></div></div><div class="TabsPanel" id="ff6f1c4f-1264-4c1f-a144-1bba8860146d-panel-4" role="tabpanel" aria-hidden="true" tabindex="0" aria-label=""><h3 class="ResponsiveHeading "></h3><div class="TabContent"><div class="RichText"></div><div class="List" id="9ad94bc4-137b-43c7-bb64-ef65117606d2" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText"><strong>Transdermal patch: </strong>For adults, one patch is applied to the upper outer arm at least 24 hours but no more than 48 hours before chemotherapy. The patch should be removed between 24 hours or up to 7 days after the administration of chemotherapy.</div></li></ul></div></div></div></div></div><div class="RichText"><strong>Adverse Effects<br></strong>Headaches are the most commonly occurring adverse effect of granisetron. Additional adverse effects include (Medscape, n.d.b.):</div><div class="Figure Wrapright  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="Tired patient with a headache in bed" title="Tired patient with a headache in bed" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/headache-1468905448-g.jpg" style="width: 300px; max-height: 200px;" class="FigureImage"></div></div></div><div class="List" id="31c58923-d64f-4516-be63-16971dc88038" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Drowsiness and/or sedation</div></li><li class="ListItem"><div class="RichText">Somnolence</div></li><li class="ListItem"><div class="RichText">Lack of energy</div></li><li class="ListItem"><div class="RichText">Abnormal physical weakness</div></li><li class="ListItem"><div class="RichText">Diarrhea</div></li><li class="ListItem"><div class="RichText">Constipation</div></li><li class="ListItem"><div class="RichText">Injections site reactions</div><div class="List" id="31c58923-d64f-4516-be63-16971dc88038---cid-d2e1349---cid-d2e1368---cid-d2e1371-" data-build=""><ul class="ListItems Disk " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Pain</div></li><li class="ListItem"><div class="RichText">Redness or discoloration</div></li><li class="ListItem"><div class="RichText">Irritation</div></li><li class="ListItem"><div class="RichText">Rash</div></li><li class="ListItem"><div class="RichText">Burning</div></li><li class="ListItem"><div class="RichText">Itching</div></li><li class="ListItem"><div class="RichText">Hives</div></li><li class="ListItem"><div class="RichText">Vesicles</div></li></ul></div></li></ul></div></div></section><section class="TitledBlock" aria-labelledby="c6ccc9de-90f2-4adc-a63b-1d4baa3ca830-title"><h1 id="c6ccc9de-90f2-4adc-a63b-1d4baa3ca830-title">Anticholinergic Agents</h1><div class="ParaBlock" id="f814b628-bf14-475a-aabd-fa3916d4df3f"><div class="RichText">Anticholinergic agents inhibit the action of acetylcholine at the muscarinic receptor. Like antihistamines, anticholinergics limit the stimulation of the vomiting center from the vestibular system (Gravatt et al., 2023).</div><div class="RichText"><strong>Scopolamine</strong></div><div class="RichText">Scopolamine is a belladonna alkaloid and is FDA-approved for the treatment of nausea with motion sickness and PONV (Riad &amp; Hithe, 2023). It has off-label indications to treat CINV. It has antiemetic, amnestic, and central sedative effects. It relaxes smooth muscle and decreases glandular secretion.</div><div class="RichText"><strong>Dosage and Administration</strong><br>Scopolamine is available as a transdermal patch and delivers a steady dose of 1.5 mg over 72 hours. The patch reaches its most optimal efficacy at 24 hours. The patch is round and about 2.5 cm in diameter. Due to its 4-hour onset, instruct patients to apply the patch at least 4 hours before being in a setting that may cause motion sickness or the night before an operative procedure. Teach the patient to the most optimal placement of the patch which is found behind the ear where there is no hair present.</div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Practice Tip: </strong>Advise the patient not to cut or alter the patch, which may jeopardize the medication delivery. Also, encourage the patient to wash their hands thoroughly to avoid visual disturbances.</div></div></div></div><div class="RichText"><strong>Adverse Effect<br></strong>Although scopolamine usually has an amnestic effect, in higher doses the drug may cause restlessness and over exuberance (Riad &amp; Hithe, 2023). More frequently reported adverse effects include:</div><div class="Figure Wrapleft  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="close-up of a dilated pupil" title="close-up of a dilated pupil" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/eye-948475878-g.jpg" style="width: 300px; max-height: 200px;" class="FigureImage"></div></div></div><div class="List" id="b50f41fc-3728-4cfc-9fd2-40eecdeeb2df" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Dilated pupils</div></li><li class="ListItem"><div class="RichText">Blurred vision</div></li><li class="ListItem"><div class="RichText">Dry mouth</div></li></ul></div><div class="RichText">Scopolamine is contraindicated in patients with angle-closure glaucoma and in those with an allergy to other belladonna alkaloids, such as atropine.</div></div></section><section class="TitledBlock" aria-labelledby="8510b1d4-f447-430d-a985-17e93cd1f17d-title"><h1 id="8510b1d4-f447-430d-a985-17e93cd1f17d-title">Antihistamines</h1><div class="ParaBlock" id="e1c98236-eb6f-494a-be37-1db65a5ee8c4"><div class="RichText">Antihistamines inhibit the action of histamine at the histamine-1 and histamine-2 receptors (Hauser et al., 2022; Gravatt et al., 2023). Antihistamines that have anti-cholinergic activity are known to reduce stimulation of the vomiting center in the vestibular apparatus by interrupting various visceral afferent pathways. This section will focus on the following:</div><div class="List" id="0b1309fb-2ad1-4e7e-a806-60462a5dc2d5" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Doxylamine/pyridoxine (Bonjesta<sup>®</sup>, Diclegis<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Diphenhydramine (Benadryl<sup>®</sup>, Unisom<sup>®</sup>, Aler-Dryl<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Meclizine (Antivert<sup>®</sup>, Bonine<sup>®</sup>)</div></li></ul></div><div class="RichText">Dimenhydrinate (Dramamine<sup>®</sup>) is another antiemetic antihistamine but will not be featured in this course.</div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Practice Tip: </strong>When antihistamines are used to treat nausea and vomiting, it is primarily associated with motion sickness. Warn patients not to drive or operate heavy machinery when taking antihistamines because they may cause drowsiness.</div></div></div></div><div class="RichText"><strong>Doxylamine</strong></div><div class="RichText">Doxylamine blocks the histamine-1 receptors that send signals to the vomiting center of the medulla oblongata. The FDA approved a combination of doxylamine with pyridoxine (an analog of vitamin B-6) for pregnancy-related nausea and vomiting that does not respond to conservative, first-line treatments such as dietary and behavior modifications. </div><div class="RichText"><strong>Dosage and Administration</strong><br>The initial dose is 20 mg doxylamine/20 mg pyridoxine (1 Bonjesta tablet or 2 Diclegis tablets) once daily at bedtime, but the dose may be increased to a maximum of 40 mg doxylamine/40 mg pyridoxine per day, dosed twice daily with Bonjeta or three times a day with Diclegis. Since this drug has an extended release, the tablet should not be altered or chewed (Brott &amp; Reddivari, 2022).</div><div class="Figure Wrapright  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="Blurred view of a hospital corridor" title="Blurred view of a hospital corridor" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/blurredview-1459714232-g.jpg" style="width: 300px; max-height: 199px;" class="FigureImage"></div></div></div><div class="RichText"><strong>Adverse Effects</strong><br>Due to the anticholinergic activity of these agents, they should be used with caution in patients with glaucoma, benign prostatic hyperplasia, asthma, or advanced age (Gravatt et al., 2023). The most reported adverse effects of doxylamine include:</div><div class="List" id="7c3dc2c8-a2b2-41b3-bd44-74e16a71556c" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Impaired judgment</div></li><li class="ListItem"><div class="RichText">Impaired coordination</div></li><li class="ListItem"><div class="RichText">Drowsiness</div></li><li class="ListItem"><div class="RichText">Blurred vision</div></li><li class="ListItem"><div class="RichText">Double vision</div></li><li class="ListItem"><div class="RichText">Urinary retention</div></li></ul></div><div class="RichText">Simultaneous use of doxylamine and a monoamine oxidase inhibitor is contraindicated (Brott &amp; Reddivari, 2022). In addition, the use of alcohol while taking doxylamine can cause significant somnolence and should be discouraged. Similarly, advise patients to use caution taking medications that depress the CNS alongside doxylamine. </div><div class="RichText"><strong>Meclizine</strong></div><div class="RichText">Meclizine is FDA-approved for the treatment of vertigo secondary to vestibular disorders (e.g., Meniere’s disease) and motion sickness, and its related symptoms (e.g., dizziness, nausea, and vomiting). Meclizine is available as an over-the-counter (OTC) product. </div><div class="RichText"><strong>Dosing and Administration</strong><br>To prevent motion sickness, it should be taken an hour before the start of an activity which may cause nausea and vomiting. The recommended dose for adults and children 12 years and older is 25 to 50 mg once daily, as needed. It is not intended for prolonged use.</div><div class="RichText"><strong>Adverse Effects<br></strong>Patients with hypersensitivity to meclizine or its active ingredients should not take this medication. Meclizine has many adverse effects, including:</div><div class="List" id="278ff773-4399-4e4c-b5d9-44276d250547" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Drowsiness</div></li><li class="ListItem"><div class="RichText">Dry mouth</div></li><li class="ListItem"><div class="RichText">Fatigue</div></li><li class="ListItem"><div class="RichText">Headache</div></li><li class="ListItem"><div class="RichText">Vomiting</div></li><li class="ListItem"><div class="RichText">Blurred vision</div></li></ul></div><div class="RichText"><strong>Diphenhydramine</strong></div><div class="List" id="be0714a6-a9ca-4018-86c8-f6d8aaa3afae" data-build=""><div class="ListPreamble">Diphenhydramine is used to treat several conditions including:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Allergies</div></li><li class="ListItem"><div class="RichText">Insomnia</div></li><li class="ListItem"><div class="RichText">Dystonia</div></li><li class="ListItem"><div class="RichText">Itching</div></li><li class="ListItem"><div class="RichText">Motion sickness and related nausea</div></li><li class="ListItem"><div class="RichText">Vertigo</div></li></ul></div><div class="Figure Wrap  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="Person struggling with vertigo" title="Person struggling with vertigo" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/vertigo-1488292424-g.gif" style="width: 500px; max-height: 282px;" class="FigureImage"></div></div></div><div class="RichText">Since diphenhydramine is sedating, it is not often used as an antiemetic (Gravatt et al., 2023). Like many antihistamines, diphenhydramine is available OTC.</div><div class="RichText"><strong>Dosing and Administration</strong><br>The normal dose for adults and children older than 12 years is 25 to 50 mg PO/IV/IM every 4 to 6 hours PRN. The adult patient should receive no more than 100 mg in a single dose. The maximum oral dose is a cumulative maximum of 300 mg in 24 hours, and the maximum IV/IM dose is 400 mg in 24 hours. In the pediatric population, the dosing is lower:</div><div class="List" id="ba394afe-fe07-41b8-beb6-fa737b37f508" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">For ages 2-5, the dose is 6.25 mg PO/IV/IM every 4 to 6 hours PRN, with a maximum dose of 37.5 mg in 24 hours.</div></li><li class="ListItem"><div class="RichText">For ages 6 to 11, the dose is 12.5 to 25 mg PO/IV/IM every 4 to 6 hours PRN, with a maximum dose of 150 mg in 24 hours.</div></li></ul></div><div class="RichText">It can be dosed up to 30 minutes before a motion sickness-inducing circumstance.</div><div class="RichText"><strong>Adverse Effects<br></strong>The more prevalent adverse effects include (Sicari &amp; Zabbo, 2022):</div><div class="List" id="99dd70b1-2f26-488f-9130-fe52ccfa2c5a" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Drowsiness</div></li><li class="ListItem"><div class="RichText">Headache</div></li><li class="ListItem"><div class="RichText">Dizziness</div></li><li class="ListItem"><div class="RichText">Diminished coordination</div></li><li class="ListItem"><div class="RichText">Hypotension</div></li><li class="ListItem"><div class="RichText">Paradoxical CNS stimulation</div></li><li class="ListItem"><div class="RichText">Diaphoresis</div></li><li class="ListItem"><div class="RichText">Cardiac effects (i.e., palpitations, tachycardia)</div></li><li class="ListItem"><div class="RichText">Dry mucous membranes</div></li><li class="ListItem"><div class="RichText">Constipation</div></li><li class="ListItem"><div class="RichText">Ataxia</div></li><li class="ListItem"><div class="RichText">Euphoria</div></li></ul></div><div class="RichText">The more significant adverse effects include QT prolongation, postrenal obstruction, and subsequent acute kidney injury.</div></div><div class="ParaBlock" id="86d1e100-2bbd-42d6-a9df-1687f93d4148"><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Practice Tip: </strong>Advise patients to avoid operating heavy machinery after taking diphenhydramine due to possible CNS depression (Sicari &amp; Zabbo, 2022). Diphenhydramine may also potentiate the effects of sedating medications. Use caution administering it to older patients due to an increased risk of falls secondary to its adverse effects.</div></div></div></div></div></section><section class="TitledBlock" aria-labelledby="9bb0c6e5-b2df-44ff-b5f1-3def44f71955-title"><h1 id="9bb0c6e5-b2df-44ff-b5f1-3def44f71955-title">Neurokinin Receptor Antagonists</h1><div class="ParaBlock" id="8ba6f19e-839e-448f-a5bb-47488814664e"><div class="List" id="8f959d4d-1fb0-4ea2-bd6d-0660e12720ea" data-build=""><div class="ListPreamble">Neurokinin receptor (NK-1) antagonists have had a significant impact on patients with CINV, since they came to the market in the early 2000s. This class has antiemetic, anxiolytic, and antidepressant qualities (Ibrahim &amp; Preuss, 2023). NK-1 antagonists inhibit the stimulus of the vomiting center centrally and peripherally. This course will highlight two NK-1 antagonists:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Aprepitant (Emend<sup>®</sup> capsules/powder for solution, Cinvanti<sup>®</sup>, Aponvie<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Fosaprepitant (Emend<sup>®</sup> for injection)</div></li></ul></div><div class="List" id="9446a2a4-9bb3-429f-b393-a275c741cb5e" data-build=""><div class="ListPreamble">Patients with hypersensitivity to this class of medications or its active ingredients should refrain from use. Concomitant use of pimozide (Orap<sup>®</sup>) is contraindicated with this medication due to raising the risk of QTc prolongation (Ritchie &amp; Kohli, 2022). Additional drug-drug interactions for NK-1 receptor antagonists include moderate to strong CYP3A4 inhibitors. Examples include the following medications:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Lomitapide (Juxtapid<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Flibanserin (Addyi<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Ivabradine (Corlanor<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Tacrolimus (Prograf<sup>®</sup>)</div></li></ul></div><div class="RichText"><strong>Aprepitant</strong></div><div class="RichText">Aprepitant has a unique ability to cross the blood-brain barrier, setting it apart from other neurokinin receptor antagonists. It also lacks a predisposition to dopamine, serotonin, or corticosteroid receptors. The result is a highly selective neurokinin receptor antagonist, making it a very effective antiemetic. Aprepitant is effective in the prophylaxis of delayed nausea in patients with CINV, in addition to nausea in those undergoing multiple rounds of chemotherapy. Aprepitant has also been approved by the FDA for the prevention of PONV in the adult population.</div><div class="RichText"><strong>Dosing and Administration<br></strong>In the preoperative setting, one 40 mg capsule of aprepitant can be given 3 hours before anesthesia induction. In patients receiving chemotherapy, an oral dose of 125 mg can be administered an hour before the Day 1 chemotherapy treatment. After this initial dose, a dose of 80 mg PO can be given on the morning of the Day 2 and 3 chemotherapy treatments.</div><div class="RichText">The IV formulation can be given as a single-dose regimen for moderately emetogenic chemotherapy of 130 mg IV, 30 mins prior to chemotherapy or as a 3-day regimen for highly emetogenic chemotherapy. Additionally, another IV formulation (Aponvie<sup>®</sup>) can be used as a 32 mg injection prior to anesthesia in PONV.</div><div class="RichText"><strong>Adverse Effects<br></strong>Generally well tolerated, the adverse effects of aprepitant are minimal, however, may be (Ritchie &amp; Kohli, 2022):</div><div class="List" id="bc7edec5-a574-4cf8-8ca3-a31a69c5e3f7" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Headache</div></li><li class="ListItem"><div class="RichText">Fatigue</div></li><li class="ListItem"><div class="RichText">Anorexia</div></li><li class="ListItem"><div class="RichText">Nausea</div></li><li class="ListItem"><div class="RichText">Diarrhea</div></li><li class="ListItem"><div class="RichText">Constipation</div></li><li class="ListItem"><div class="RichText">Abnormal physical weakness</div></li><li class="ListItem"><div class="RichText">Hiccups</div></li><li class="ListItem"><div class="RichText">Serious infections (rare)</div></li></ul></div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Practice Tip: </strong>This medication lowers the efficacy of oral contraceptives. Inform patients using oral contraceptives to utilize a backup form of contraception or practice abstinence for one month after taking this medication.</div></div></div></div><div class="CustomNote " data-popup="" style="width: auto; height: auto;"><div class="Content"><div class="SimpleBlock"><div class="RichText"><strong>Diversity, Equity, Inclusivity, and Belonging Considerations</strong>: Aprepitant is an expensive medication; before prescribing this drug, determine if the patient’s insurance will cover the cost or if the patient can afford to self-pay. There is no evidence that this medication is any better than ondansetron.</div></div></div></div><div class="RichText"><strong>Fosaprepitant</strong></div><div class="RichText">Fosaprepitant is indicated for the prophylaxis of delayed and acute CINV, particularly with moderately to highly emetic chemotherapy treatments.</div><div class="RichText"><strong>Dosing and Administration</strong><br>For adults, the dose is 150 mg IV for the first day of chemotherapy only. In the pediatric population, children ages 6 months to 17 years, can receive a single dose of fosaprepitant intravenously on the first day of chemotherapy. The rate of infusion for this dose is age-dependent, with the dose given IV over an hour for patients aged 6 months to under 12 years old. Children aged 12 to 17 may receive IV fosaprepitant over 30 minutes, and adults can receive the dose over 20 to 30 minutes.</div><div class="RichText"><strong>Adverse Effects</strong></div><div class="List" id="792a8348-8027-45fe-88e0-191bdb5dd215" data-build=""><div class="ListPreamble">The more common adverse effects of fosaprepitant include (Medscape, n.d.a.):</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Low white blood cell count</div></li><li class="ListItem"><div class="RichText">Fatigue</div></li><li class="ListItem"><div class="RichText">Abnormal physical weakness</div></li><li class="ListItem"><div class="RichText">Diarrhea</div></li></ul></div><div class="RichText">Less prevalent adverse effects include those with skin involvement, such as a rash, hives, or itching (Medscape, n.d.a.). Stevens-Johnson syndrome and toxic epidermal necrolysis have also been reported as an adverse effect.</div></div></section><section class="TitledBlock" aria-labelledby="f5f8592b-5aad-4d39-9ec8-1571772a719c-title"><h1 id="f5f8592b-5aad-4d39-9ec8-1571772a719c-title">Glucocorticoids</h1><div class="ParaBlock" id="16d03898-9356-41e4-80de-c4e24a03285e"><div class="RichText">Glucocorticoids are most often used for their anti-allergic and anti-inflammatory properties, but they are also effective for preventing nausea and vomiting. Specifically, dexamethasone has a role in the prevention of CINV and PONV (Hesketh et al., 2020).</div><div class="RichText"><strong>Dexamethasone</strong></div><div class="RichText">The indication for CINV, PONV, and altitude sickness is off label (Johnson et al., 2023). For the purposes of PONV prevention, dexamethasone’s efficacy is optimized if given prior to anesthesia induction. It is endorsed by the American Society of Clinical Oncology (ASCO) for use in CINV prevention, where it typically given alongside a NK-1 receptor antagonist and 5-HT3 receptor antagonist (Hesketh et al., 2020).</div><div class="RichText"><strong>Dosing and Administration</strong><br>For CINV, 12 to 20 mg of oral or IV dexamethasone may be given prior to the initial chemotherapy, dependent upon which concomitant NK-1 receptor antagonist is chosen (Hesketh et al., 2020). On subsequent days of chemotherapy, the patient can receive 8 mg of IV or oral dexamethasone (i.e., one dose on day 2 and twice daily on days 3-4).</div><div class="RichText">For PONV, dexamethasone has been used in a range of doses, but is commonly dosed between 4 mg to 10 mg IV (Myles &amp; Corcoran, 2021).</div><div class="RichText"><strong>Adverse Effects<br></strong>Some of the more prevalent side effects of dexamethasone include:</div><div class="List" id="c506fd2c-0d18-4766-b51d-91fd4f39a7ca" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">An enhanced appetite</div></li><li class="ListItem"><div class="RichText">Trouble sleeping</div></li><li class="ListItem"><div class="RichText">Rash</div></li><li class="ListItem"><div class="RichText">Headache</div></li><li class="ListItem"><div class="RichText">Dizziness</div></li><li class="ListItem"><div class="RichText">Swelling in the extremities</div></li><li class="ListItem"><div class="RichText">Mood changes</div></li><li class="ListItem"><div class="RichText">Acne</div></li><li class="ListItem"><div class="RichText">Diaphoresis</div></li></ul></div><div class="RichText">Dexamethasone should be avoided in patients with an active fungal infection due to its potential to cause exacerbation. Use caution in patients with ocular herpes simplex due to the risk of corneal perforation.</div></div></section><section class="TitledBlock" aria-labelledby="066d00ef-5ef5-485c-a9d4-d375c5e78ce9-title"><h1 id="066d00ef-5ef5-485c-a9d4-d375c5e78ce9-title">Benzodiazepines</h1><div class="ParaBlock" id="6df773de-926f-4ddc-9225-413b578de911"><div class="RichText">Benzodiazepines suppress the activity of dopamine at the CTZ, resulting in a central antiemetic effect. This course will highlight the antiemetic effects of lorazepam (Ativan<sup>®</sup>).</div><div class="RichText"><strong>Lorazepam</strong></div><div class="RichText">Lorazepam has an off-label use for the treatment of CINV symptoms, especially for anticipatory and breakthrough symptoms.</div><div class="RichText"><strong>Dosing and Administration<br></strong>A dose of 0.5 to 2 mg of lorazepam can be given every 6 hours PRN through the following routes:</div><div class="List" id="7cebcd7c-0f68-4a63-9315-908708719db9" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Oral</div></li><li class="ListItem"><div class="RichText">IV</div></li><li class="ListItem"><div class="RichText">IM</div></li></ul></div><div class="RichText"><strong>Adverse Effects<br></strong>CNS and respiratory depression are the most notable adverse effects of lorazepam, which are dose dependent (Ghiasi et al., 2023). For this reason, caution should be used with the concomitant use of other medications causing CNS and respiratory depression. It should not be used in the neonatal or infant population or in patients with acute narrow-angle glaucoma, sleep apnea, or severe respiratory impairment (unless intubated). Additional common adverse effects include:</div><div class="List" id="5d6c64a0-37d9-4018-9948-94953f677951" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Hypotension</div></li><li class="ListItem"><div class="RichText">Hypoventilation (i.e., intravenous administration)</div></li><li class="ListItem"><div class="RichText">Dizziness</div></li><li class="ListItem"><div class="RichText">Dysarthria</div></li><li class="ListItem"><div class="RichText">Constipation</div></li><li class="ListItem"><div class="RichText">Loss of inhibition</div></li><li class="ListItem"><div class="RichText">Ataxia</div></li><li class="ListItem"><div class="RichText">Urinary retention</div></li><li class="ListItem"><div class="RichText">Incontinence</div></li><li class="ListItem"><div class="RichText">Liver enzyme elevation</div></li><li class="ListItem"><div class="RichText">Acute hepatic injury (rare)</div></li></ul></div></div></section><section class="TitledBlock" aria-labelledby="704daed7-d9ce-4a19-be81-9423c99466ce-title"><h1 id="704daed7-d9ce-4a19-be81-9423c99466ce-title">Atypical Antipsychotics</h1><div class="ParaBlock" id="60d3805c-3fce-455e-a81b-1ba415c7fae3"><div class="RichText">Olanzapine (Zyprexa<sup>®</sup>) is the only atypical antipsychotic with antiemetic qualities (Saudemont et al., 2020).</div><div class="RichText"><strong>Olanzapine</strong></div><div class="RichText">Olanzapine has been effective in the prophylaxis and treatment of CINV (Saudemont et al., 2020). It is particularly effective in the treatment of delayed CINV with highly or moderate chemotherapy treatments (Perwitasari et al., 2011). Due to its affinity for dopamine and serotonin receptors in the vomiting center, it has a central antiemetic effect (Saudemont et al., 2020; Thomas &amp; Saadabadi, 2022).</div><div class="RichText"><strong>Dosing and Administration</strong><br>Olanzapine can be administered orally, via traditional or disintegrating tablet, and parentally via injection. For the purpose of preventing nausea and vomiting, the dose is dependent on the chemotherapy regimen but is commonly 5 to 10 mg on the first 4 to 5 days of chemotherapy (Saudemont et al., 2020).</div><div class="RichText"><strong>Adverse Effects<br></strong>The disintegrating oral form of olanzapine may comprise of phenylalanine; therefore, its use is contraindicated in patients with PKU. In addition, this drug increases the risk of mortality in patients with dementia, and among those with dementia, older patients have an increased risk of a cerebrovascular accident with this drug. Adverse effects of this medication include:<strong></strong></div><div class="List" id="9fb2c961-11bd-4ade-a3df-fd0c31ee1ff2" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Weight gain as a result of an enhanced appetite</div></li><li class="ListItem"><div class="RichText">Reduced insulin sensitivity</div></li><li class="ListItem"><div class="RichText">Hypothermia</div></li><li class="ListItem"><div class="RichText">Swelling</div></li><li class="ListItem"><div class="RichText">Extrapyramidal symptoms</div></li><li class="ListItem"><div class="RichText">Neuroleptic malignant syndrome</div></li><li class="ListItem"><div class="RichText">Neutropenia</div></li><li class="ListItem"><div class="RichText">Thrombocytopenia</div></li></ul></div></div></section><section class="TitledBlock" aria-labelledby="b0764021-bc9b-4bdd-a5bc-913b3eab7b64-title"><h1 id="b0764021-bc9b-4bdd-a5bc-913b3eab7b64-title">Cannabinoids</h1><div class="ParaBlock" id="56825428-d426-4dc7-af15-bba5706cf06a"><div class="List" id="c29cf02e-2a48-4fc7-808f-6fd9fc5bb28e" data-build=""><div class="ListPreamble">The endocannabinoid system in the GI tract participates in the control of intestinal functions, including nausea and vomiting. Therefore, many cannabinoid-related agents have been investigated for their roles in digestive pathologies (Uranga et al., 2018). While this class of drugs has shown efficacy in the treatment of CINV, they are not preferred agents and their use should be pursued cautiously owing to the risk of side effects (Gravatt et al., 2023). Marijuana is not included in guidelines or best practices for the treatment of CINV, and its use is legally and therapeutically controversial (Todaro, 2012). This course will highlight two cannabinoids:</div><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Dronabinol (Marinol<sup>®</sup>, Syndros<sup>®</sup>)</div></li><li class="ListItem"><div class="RichText">Nabilone (Cesamet<sup>®</sup>)</div></li></ul></div><div class="RichText"><strong>Dronabinol</strong></div><div class="RichText">Dronabinol is a synthetic preparation of tetrahydrocannabinol, which is considered the chief naturally occurring psychoactive constituent of the cannabis plant (O’Donnell et al., 2022). Dronabinol is sometimes used to treat emesis in patients undergoing cancer treatment who have <strong>exhausted all conventional antiemetic options without success.</strong> This drug has also been approved for the treatment of anorexia in patients with AIDS. Dronabinol is a Schedule III controlled substance.</div><div class="RichText">Dronabinol has been studied as monotherapy for nausea and vomiting, as well as in combination with other antiemetics. Currently, there is not enough data to recommend the routine use of dronabinol as an antiemetic for CINV. </div><div class="RichText"><strong>Dosing and Administration</strong><br>This drug is available as an oral capsule and an oral solution. The recommended starting dose of oral dronabinol is 5 mg administered 1 to 3 hours before chemotherapy. The doses can be repeated every 2 to 4 hours for a total of four to six doses per day.</div><div class="RichText"><strong>Adverse Effects<br></strong>Patients should refrain from operating heavy machinery or driving while taking this medication until their tolerance of the drug and their ability to drive or operate machinery has been evaluated (O’Donnell et al., 2022). Patients with a history of psychiatric disorders should avoid this drug. Patients should refrain from concomitant use of psychoactive substances (e.g., alcohol) while taking dronabinol due to a risk of enhanced psychotropic effects. Adverse effects of dronabinol include:<strong></strong></div><div class="List" id="24425a45-73d1-403c-829f-309643e8ced9" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Seizures</div></li><li class="ListItem"><div class="RichText">Paradoxical nausea and vomiting</div></li><li class="ListItem"><div class="RichText">Hemodynamic instability</div></li><li class="ListItem"><div class="RichText">Physical and mental impairment</div></li></ul></div><div class="RichText"><strong>Nabilone</strong></div><div class="RichText">Nabilone is a synthetic cannabinoid that can be used for the treatment of CINV (Medscape, n.d.c.). Nabilone is not intended as a first-line agent, nor should it be used on an as-needed basis. Nabilone is a Schedule II controlled substance. </div><div class="RichText"><strong>Dosing and Administration</strong><br>The usual dose in adults is 1 mg to 2 mg every 8 to 12 hours with the initial dose given 1 to 3 hours before chemotherapy. A maximum daily dose is 6 mg.</div><div class="RichText"><strong>Adverse Effects<br></strong>Common adverse effects for nabilone include (Medscape, n.d.c.):</div><div class="List" id="65682306-9212-42fc-b9c1-4a48e84206e5" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Drowsiness </div></li><li class="ListItem"><div class="RichText">Vertigo</div></li><li class="ListItem"><div class="RichText">Ataxia</div></li><li class="ListItem"><div class="RichText">Dry mouth</div></li><li class="ListItem"><div class="RichText">Blurred vision and other visual disturbances</div></li><li class="ListItem"><div class="RichText">Difficulty concentrating</div></li><li class="ListItem"><div class="RichText">Trouble sleeping</div></li><li class="ListItem"><div class="RichText">Euphoria and dysphoria</div></li><li class="ListItem"><div class="RichText">Headache</div></li><li class="ListItem"><div class="RichText">Disorientation</div></li><li class="ListItem"><div class="RichText">Orthostatic hypotension</div></li><li class="ListItem"><div class="RichText">Tachycardia</div></li></ul></div><div class="RichText">Nabilone is contraindicated in patients with a hypersensitivity to cannabinoids and those with a history of psychotic reactions (Medscape, n.d.c.). Use caution with patients with severe hepatic impairment or in those who are emotionally disturbed. Patients should refrain from concomitant use of psychoactive substances (e.g., alcohol) while taking nabilone due to a risk of enhanced psychotropic effects. The operation of heavy machinery should be avoided while taking this medication.</div></div></section><section class="TitledBlock" aria-labelledby="60375425-f504-46e4-8ab4-b1d4789614fa-title"><h1 id="60375425-f504-46e4-8ab4-b1d4789614fa-title">Alternative Treatments</h1><div class="ParaBlock" id="b726bec8-a8cf-4091-bd0f-246d169fd555"><div class="RichText"><strong>Herbal Supplements</strong></div><div class="RichText">Many herbal supplements are sold in health food stores and pharmacies as a treatment for nausea and vomiting. However, this use is not approved by the FDA and should be considered cautiously.</div><div class="Figure Wrapright  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="Ginger root pictured next to ginger tea" title="Ginger root pictured next to ginger tea" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/gingerroot-170488043-g.jpg" style="width: 300px; max-height: 450px;" class="FigureImage"></div></div></div><div class="RichText"><strong>Ginger</strong><br>Ginger has been shown to be beneficial for pregnancy-related nausea and vomiting, CINV, PONV, and medication-related nausea and vomiting (Heckroth et al., 2021). The chemical components in ginger, specifically gingerol, zingerone, and shogaol, work in the peripheral and central nausea and vomiting pathways. These chemicals act through neurokinin and serotonin receptors. Ginger has been found to accelerate gastric emptying, enhance gastric tone, and stimulate gastric antral contractions (Hu et al., 2011; Lete &amp; Allue, 2016). Though generally considered safe, the appropriate dose and duration of treatment have not been defined (Lete &amp; Allue, 2016). Adverse effects of ginger are infrequent but include heartburn and belching.</div><div class="RichText"><strong>Bioelectric Neuromodulation</strong></div><div class="RichText">A therapy used in the treatment of Parkinson’s disease, chronic pain, and psychiatric disorders, electrical stimulation has emerged as a potential treatment for chronic nausea and vomiting (Heckroth et al., 2021). Clinical studies have unveiled improvement in the reduction of vomiting episodes and the symptoms of gastroparesis. <strong>Gastric electrical stimulation</strong> (GES) has also been studied on patients without gastroparesis who experience nausea and vomiting. There are two types of GES: Low frequency with high energy stimulation and high frequency with low energy stimulation. Both can be used in the treatment of gastroparesis.</div><div class="List" id="ed044bf4-86f9-4746-812c-0e684c863197" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">Research on <strong>high energy and low frequency</strong> electrical stimulation reveals that it may stabilize gastric dysrhythmias and speed gastric emptying without enhancing nausea and vomiting. However, it is not approved by the FDA.</div></li><li class="ListItem"><div class="RichText">Studies found that electrical stimulation with <strong>low energy and high frequency</strong> revealed a greater reduction of nausea and vomiting in patients with gastroparesis; however, its effect on gastric emptying yielded insignificant results. Due to its low energy consumption, Medtronic developed an implantable device with this technology, which has been FDA-approved for patients with gastroparesis who have exhausted other medical options.</div></li></ul></div></div></section><section class="TitledBlock" aria-labelledby="eb652290-02f2-4549-be6f-b3e7642b0ef5-title"><h1 id="eb652290-02f2-4549-be6f-b3e7642b0ef5-title">Review</h1><div class="ParaBlock" id="ab595225-17ca-4cee-9028-681676fa2b86"><div class="RichText"></div></div></section><div class="QuestionBlock" id="guid_f1ffe99a-9b8d-440a-880c-d6e531cffc2d" data-guid="f1ffe99a-9b8d-440a-880c-d6e531cffc2d"><div id="guid_747285c5-5cf5-4c74-9f8a-85c0f9f68281" class="MultipleChoiceQuestion Question" data-guid="747285c5-5cf5-4c74-9f8a-85c0f9f68281" data-view="MultipleChoiceCheckbox"><div class="MultipleChoiceInnerWrap QuestionInnerWrap"><a title="Flag/Unflag this Question" class="QuestionFlagIcon">Flag/Unflag this Question<svg viewBox="0 0 24 24" class="SVGIcon FlaggedIcon" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="flag"><path d="M1 23 V1 H20 L15 8 L20 16 L1 16" stroke-width="2" fill="inherit"></path></g></svg><svg viewBox="0 0 24 24" class="SVGIcon UnflaggedIcon" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="unflag"><path d="M1 23 V1 H20 L15 8 L20 16 L1 16" stroke-width="2" fill="none"></path></g></svg></a><div class="MultipleChoiceQuestionStem QuestionStem"><h3><div class="Figure Wrap  ImageBehavior-"><div class="FigureOuterWrap"><div class="FigureInnerWrap"><img alt="Cancer patient" title="Cancer patient" aria-label="" src="media/_RE-ORG/ACU/_NAR/POAEM/cancer-1356221138-g.jpg" style="width: 500px; max-height: 333px;" class="FigureImage"></div></div></div><div class="RichText">Brody has been suffering from chemotherapy-induced nausea and vomiting and is anticipating their next cycle of treatment. So far, they have tried one antiemetic for CINV, but it did not control their nausea. They have bipolar disorder, for which they self-medicate with alcohol. With the next cycle approaching, your patient requests dronabinol. What are the reasons for refraining from dronabinol use for CINV prevention during the upcoming cycle of chemotherapy? <strong>Select all that apply.</strong></div></h3></div><ul class="MultipleChoiceQuestionOptions QuestionOptions"><li class="MultipleChoiceQuestionOptionWrapper QuestionOptionWrapper"><label><div class="MultipleChoiceQuestionOptionInputWrapper"><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Correct" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="correct"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon AlsoCorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="alsocorrect"><path d="M0 0h24v24H0z" fill="none"></path><path d="M12 2C6.47 2 2 6.47 2 12s4.47 10 10 10 10-4.47 10-10S17.53 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8z"></path></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Incorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="incorrect"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g></svg><input tabindex="10" id="option_747285c5-5cf5-4c74-9f8a-85c0f9f68281_1" class="MultipleChoiceQuestionOption QuestionOption" type="checkbox" value="1"></div><div class="MultpleChoiceQuestionOptionDistractorWrapper"><span class="MultipleChoiceQuestionOptionStem QuestionOptionStem"><div class="RichText">It is a controlled substance.</div></span><span class="ResponseFeedback Feedback"></span></div></label></li><li class="MultipleChoiceQuestionOptionWrapper QuestionOptionWrapper"><label><div class="MultipleChoiceQuestionOptionInputWrapper"><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Correct" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="correct"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon AlsoCorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="alsocorrect"><path d="M0 0h24v24H0z" fill="none"></path><path d="M12 2C6.47 2 2 6.47 2 12s4.47 10 10 10 10-4.47 10-10S17.53 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8z"></path></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Incorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="incorrect"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g></svg><input tabindex="10" id="option_747285c5-5cf5-4c74-9f8a-85c0f9f68281_2" class="MultipleChoiceQuestionOption QuestionOption" type="checkbox" value="2"></div><div class="MultpleChoiceQuestionOptionDistractorWrapper"><span class="MultipleChoiceQuestionOptionStem QuestionOptionStem"><div class="RichText">Brody has a history of alcohol use.</div></span><span class="ResponseFeedback Feedback"></span></div></label></li><li class="MultipleChoiceQuestionOptionWrapper QuestionOptionWrapper"><label><div class="MultipleChoiceQuestionOptionInputWrapper"><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Correct" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="correct"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon AlsoCorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="alsocorrect"><path d="M0 0h24v24H0z" fill="none"></path><path d="M12 2C6.47 2 2 6.47 2 12s4.47 10 10 10 10-4.47 10-10S17.53 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8z"></path></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Incorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="incorrect"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g></svg><input tabindex="10" id="option_747285c5-5cf5-4c74-9f8a-85c0f9f68281_3" class="MultipleChoiceQuestionOption QuestionOption" type="checkbox" value="3"></div><div class="MultpleChoiceQuestionOptionDistractorWrapper"><span class="MultipleChoiceQuestionOptionStem QuestionOptionStem"><div class="RichText">Brody has a psychiatric disorder.</div></span><span class="ResponseFeedback Feedback"></span></div></label></li><li class="MultipleChoiceQuestionOptionWrapper QuestionOptionWrapper"><label><div class="MultipleChoiceQuestionOptionInputWrapper"><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Correct" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="correct"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon AlsoCorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="alsocorrect"><path d="M0 0h24v24H0z" fill="none"></path><path d="M12 2C6.47 2 2 6.47 2 12s4.47 10 10 10 10-4.47 10-10S17.53 2 12 2zm0 18c-4.41 0-8-3.59-8-8s3.59-8 8-8 8 3.59 8 8-3.59 8-8 8z"></path></g></svg><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Incorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="incorrect"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g></svg><input tabindex="10" id="option_747285c5-5cf5-4c74-9f8a-85c0f9f68281_4" class="MultipleChoiceQuestionOption QuestionOption" type="checkbox" value="4"></div><div class="MultpleChoiceQuestionOptionDistractorWrapper"><span class="MultipleChoiceQuestionOptionStem QuestionOptionStem"><div class="RichText">Brody has only tried one conventional antiemetic for CINV.</div></span><span class="ResponseFeedback Feedback"></span></div></label></li></ul><div class="MultipleChoiceQuestionSubmitWrapper"><div class="QuestionSubmitWrapper"><button class="Button QuestionSubmit" title="Submit"><svg viewBox="0 0 24 24" class="SVGIcon " preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="submit"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g></svg><span>Submit</span></button><div class="AttemptCounter"></div></div></div><div class="QuestionSupplementOuterWrapper Disabled"><div class="QuestionSupplementToggleIcon" title="Extra Information"></div><div class="QuestionSupplementInnerWrapper"><div class="FeedbackWrapper"><div class="PositiveFeedback"><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Correct" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="correct"><polygon points="9,16.2 4.8,12 3.4,13.4 9,19 21,7 19.6,5.6 "></polygon></g></svg><div class="FeedbackContent"></div></div><div class="NegativeFeedback"><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Incorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="incorrect"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g></svg><div class="FeedbackContent"></div></div><div class="IncorrectNotice"><svg viewBox="0 0 24 24" class="SVGIcon FeedbackIcon Incorrect" preserveAspectRatio="xMidYMid meet" width="24px" height="24px"><g ref="incorrect"><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"></path><path d="M0 0h24v24H0z" fill="none"></path></g></svg>Incorrect, try again</div></div></div></div></div></div></div><section class="TitledBlock" aria-labelledby="f5aa7294-8987-459a-b7e9-f51df4338615-title"><h1 id="f5aa7294-8987-459a-b7e9-f51df4338615-title">Key Takeaways</h1><div class="ParaBlock" id="d072343b-9569-452e-8e4d-134a1219df5c"><div class="List" id="fe907877-010f-4179-a3a8-df8298622894" data-build=""><ul class="ListItems Bullet " style=" counter-reset: list 0;"><li class="ListItem"><div class="RichText">A wide variety of antiemetics are available to reduce the effects of nausea and vomiting. Care must be given in deciding which medication is the most appropriate for your patient. Ensure a thorough health history is completed to safeguard your patient from preventable adverse effects.</div></li><li class="ListItem"><div class="RichText">Nonpharmacological treatments may be appropriate for some patients, but when drug therapy is needed, the choice of agent should be based on the etiology of nausea, as well as the presence and severity of vomiting, comorbidities, and patient-specific preferences and factors (Gravatt et al., 2023).</div></li></ul></div></div></section></div></div></div></div></div></div></body></html>